Wanbury Pharma Limited - pharma in Navi Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN U33119MH2012PLC237381 Incorporated 31 October 2012 ROC Mumbai HQ Navi Mumbai, Maharashtra, India
Active Public Limited Company pharma
Authorised capital
₹1 Cr
Registered with MCA
Paid-up capital
₹5 Lakh
Issued & subscribed
Company age
14 yrs
Est. 2012
Directors on board
3
As per MCA filings
Active GSTINs
1
GST registered
Brands
1
Associated brands
Last financials
Mar 2025
Balance sheet date
Last AGM
30 Sep 2025
Annual general meeting

About Wanbury Pharma Limited

Data last updated:

Wanbury Pharma Limited is a public limited company based in Navi Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 31 October 2012 and has been in existence for over 14 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U33119MH2012PLC237381. Its GSTIN is 27AABCW3130H1ZK (Maharashtra).

The company has an authorised share capital of ₹1 Cr and a paid-up capital of ₹5 Lakh. It is led by directors including Vijaykumar Shivaji Ayare and Venkat Kumar Ketha.

Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at D – 28/11 MIDC Ttc Industrial Area Turbhe, Navi Mumbai, Maharashtra, India – 400706.

The company is associated with 1 brand: Wanbury Limited.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website wanbury.com.

Company details

CIN U33119MH2012PLC237381
Registration Number 237381
Incorporation Date 31 October 2012
ROC Mumbai
Listing Status Unlisted
Company Status Active
Compliance Status Active Compliant

Contact details

Wanbury Pharma Limited's registered office is in Navi Mumbai, Maharashtra. Its website is wanbury.com. Its e-mail address is in the company report.

  • Email
  • Registered Address
    D – 28/11 MIDC Ttc Industrial Area Turbhe, Navi Mumbai, Maharashtra, India – 400706
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Wanbury Pharma Limited, buy the company report.

Comprehensive company report
Wanbury Pharma Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Wanbury Pharma operates one associated brand: Wanbury Limited. Each brand links to its own profile.

BrandDescriptionWebsite
Anti-diabetic drugs and active pharmaceutical ingredients are manufactured.wanbury.com

Financials of Wanbury Pharma Limited

FY 2025 filings available

Financial Statement Summary

MetricsFY 2021-22FY 2020-21FY 2019-20FY 2018-19FY 2017-18
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA
Profit Before Tax
Tax Expense
Net Profit (PAT)
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2021-22FY 2020-21FY 2019-20FY 2018-19FY 2017-18
Profitability
EBITDA Margin
Net Profit Margin
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Wanbury Pharma Limited, buy the company report.

Board of directors of Wanbury Pharma Limited

Wanbury Pharma has 3 current directors and 4 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Vijaykumar Shivaji AyareDirector31 Oct 201214 Years 0 MonthsCurrent
Venkat Kumar KethaDirector15 Dec 20223 Years 11 MonthsCurrent
Sunil Vasudev KotyankarDirector15 Dec 20223 Years 11 MonthsCurrent

Auditor

Wanbury Pharma Limited is audited by KAPOOR & PAREKH ASSOCIATES for the financial year 2022.

Auditor firmFinancial yearFirm registration number
KAPOOR & PAREKH ASSOCIATESFY 2022104803W

Shareholding

The shareholding of Wanbury Pharma Limited is on record for 5 financial years, the latest being FY 2021, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2021FY 2020FY 2019FY 2018FY 2017
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of Wanbury Pharma Limited, buy the company report.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Wanbury Pharma Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

GST

Wanbury Pharma has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
27AABCW3130H1ZKMaharashtraActive01 Jul 2017

To see the full GST registrations and return filing status of Wanbury Pharma Limited, buy the company report.

Recent activity

Wanbury Pharma Limited has 7 board changes on record since 2012: 3 appointments and 4 cessations. The latest: Sunil Vasudev Kotyankar was appointed as Director on 15 Dec 2022.

AGM
Wanbury Pharma Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Wanbury Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai.
Appointed
Sunil Vasudev Kotyankar was appointed as Director.
Appointed
Venkat Kumar Ketha was appointed as Director.
Ceased
Ravikant Keshav Alhat ceased to be Additional Director.
Ceased
Indranil Chakraborty ceased to be Director.
Ceased
Vivek Ishwar Hebbar ceased to be Additional Director.
Ceased
Anand Lakshminarayan Kasturi ceased to be Director.
Appointed
Vijaykumar Shivaji Ayare was appointed as Director.
Incorporation
31 Oct 2012
Wanbury Pharma Limited was registered on 31 Oct 2012 with Roc Mumbai & aged 14 years 18 days as per MCA records.

Frequently asked questions

Wanbury Pharma is an active public limited company based in Navi Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 31 October 2012 (14+ years old) and is registered under CIN U33119MH2012PLC237381.

Wanbury Pharma has 3 current directors:

The latest financial statements of Wanbury Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Wanbury Pharma is 27AABCW3130H1ZK, registered in Maharashtra.

The CIN (Corporate Identification Number) of Wanbury Pharma is U33119MH2012PLC237381. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Wanbury Pharma was incorporated on 31 October 2012, making it 14+ years old. It is registered with the Registrar of Companies, Mumbai.

Sunil Vasudev Kotyankar was appointed as Director on 15 Dec 2022. Venkat Kumar Ketha was appointed as Director on 15 Dec 2022. Ravikant Keshav Alhat ceased to be Additional Director on 30 Sep 2016. Wanbury Pharma has 7 board changes on record in total.

Wanbury Pharma can be reached through the website wanbury.com. Its registered office is in Navi Mumbai, Maharashtra, India.

The registered office of Wanbury Pharma is at D – 2811 MIDC Ttc Industrial Area Turbhe, Navi Mumbai, Maharashtra, India – 400706.

Wanbury Pharma operates in the pharma industry, in the drug formulation and development segment.